Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate to Severe Asthma Clear all
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

NCT04570657
View directory record Official record
Conditions
Asthma
Interventions
MEDI3506, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Bakersfield, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Completed No phase listed Observational

Patterns of Neurocircuitry Activation In Severe Asthma

NCT03230188
View directory record Official record
Conditions
Lung Diseases
Interventions
functional Magnetic Resonance Imaging (research grade), Cognitive Function Testing (non-diagnostic), Asthma and Psychological Questionnaires (non-diagnostic)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

NCT03299686
View directory record Official record
Conditions
Asthma
Interventions
CJM112, Placebo to CJM112
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Fullerton, California • Riverside, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595
View directory record Official record
Conditions
Asthma
Interventions
QBX258, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

NCT00330070
View directory record Official record
Conditions
Asthma
Interventions
IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily
Drug
Lead sponsor
Inflazyme Pharmaceuticals Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2007 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 4 Interventional

CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma

NCT07241117
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Implementation bundle
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958
View directory record Official record
Conditions
Moderate-to-severe Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

NCT00139152
View directory record Official record
Conditions
Lung Disease
Interventions
Placebo, Xolair
Drug
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Omaha, Nebraska • Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576
View directory record Official record
Conditions
Asthma
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 4 Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

NCT04203797
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 3 Interventional

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

NCT00747318
View directory record Official record
Conditions
Asthma
Interventions
SKP FlutiForm HFA pMDI
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 2, 2026, 8:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
povorcitinib, placebo, ICS-LABA
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
KT-621, Placebo
Drug · Other
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Lancaster, California • Long Beach, California • Northridge, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Phase 2 Interventional

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

NCT07301255
View directory record Official record
Conditions
Asthma
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Jose, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

NCT04946318
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 2, 2026, 8:10 AM EDT
Recruiting Not applicable Interventional

PULmonary Stimulation for Asthma Relief

NCT07709754
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Spinal Cord Stimulation
Device
Lead sponsor
Spiro Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Denver, Colorado • Gainseville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 8:10 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults

NCT02153541
View directory record Official record
Conditions
Asthma
Interventions
Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate
Drug · Other
Lead sponsor
Global United Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 2, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation

NCT01515995
View directory record Official record
Conditions
Asthma
Interventions
Nebulized magnesium sulfate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 2, 2026, 8:10 AM EDT
Not listed No phase listed Observational

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

NCT04462224
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 2, 2026, 8:10 AM EDT